Continuous Ambulatory Peritoneal Dialysis in a Patient with Human Immunodeficiency Virus Infection  by Wong, Kim-Ming et al.
52 Hong Kong J Nephrol • April 2004 • Vol 6 • No 1
Case Report
Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China.
Address correspondence and reprint requests to: Dr. Kim-Ming Wong, Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne
Road, Kowloon, Hong Kong SAR, China.
Fax: (+852) 2781-1766; E-mail: wongkmf@ha.org.hk
Continuous Ambulatory Peritoneal Dialysis in a Patient
with Human Immunodeficiency Virus Infection
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We report the case of a female patient with human immunodeficiency virus (HIV) receiving highly active
antiretroviral therapy (HAART) who developed end-stage renal failure requiring continuous ambulatory
peritoneal dialysis (CAPD). She experienced polymicrobial CAPD-associated peritonitis and died about 1
month after initiation of CAPD. Although CAPD is an effective dialytic therapy, infection remains its Achilles’
heel. The potential risk of HIV transmission by peritoneal dialysis effluent should be noted. HAART dose
should be adjusted according to renal function to minimize adverse drug effects. [Hong Kong J Nephrol 2004;
6(1):52–5]
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CASE REPORT
A 67-year-old lady had had a history of hypertension
since 1980, but she did not seek regular medical advice.
In May 2001, she tested positive for anti-human
immunodeficiency virus (HIV) after her husband was
diagnosed with acquired immunodeficiency syndrome
(AIDS). At the same time, she was found to have im-
paired renal function, with a serum creatinine level of
230 +M. Autoimmune markers, including antinuclear
factor and anti-neutrophil cytoplasmic antibody, were
negative. Ultrasound kidney examination revealed mul-
tiple simple cysts together with evidence of chronic
parenchymal disease in both kidneys. Renal biopsy was
not performed in view of the chronic nature of the di-
sease. Anti-hypertensive therapy was adjusted for better
blood pressure control.
The patient had had localized herpes zoster infection
in September 2001 and Escherichia coli septicemia sec-
ondary to urinary tract infection requiring hospital-
ization in November 2001. In view of the drop in CD4
lymphocyte count to 261 cells/+L associated with an
increase in viral RNA load to 164 = 1,000 copies/mL
in February 2003, highly active antiretroviral therapy
(HAART) consisting of didanosine, lamivudine and
nevirapine was started. The patient’s renal function
progressively deteriorated and reached end-stage renal
failure (ESRF) in June 2003, with a serum creatinine
level of 800 +M. The HAART dose was adjusted
according to renal function. She was subsequently
prescribed intermittent peritoneal dialysis in July 2003
and switched to continuous ambulatory peritoneal
dialysis (CAPD) in August 2003.
Despite HAART (dose adjusted according to renal
function: lamivudine 50 mg daily, stavudine 20 mg
daily and nevirapine 200 mg twice daily), the CD4
lymphocyte count remained low (224 cells/+L). She
developed CAPD-associated peritonitis 3 weeks after
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CAPD in an HIV-positive patient
commencement of CAPD and developed septic shock
attributed to multiple organisms, including extended-
spectrum `-lactamase resistant E. coli, Klebsiella
species, Streptococcus milleri, coliform organisms,
Candida glabrata and Candida tropicalis. No evidence
of bowel perforation was detected clinically. She re-
ceived broad-spectrum antibiotics including vanco-
mycin, piperacillin-tazobactam, amikacin and am-
photericin B therapy to treat the peritonitis. The Tenck-
hoff catheter was removed. However, her condition
deteriorated rapidly and she died 2 weeks after hospital
admission.
DISCUSSION
HIV-positive patients are at risk of developing ESRF
attributed to HIV-associated nephropathy (HIVAN)
and other types of glomerulonephritis [1]. HIV infec-
tion is endemic in Hong Kong. As of August 2003, the
cumulative number of reported HIV cases in Hong
Kong reached 2,116 [2]. Given the observed low
incidence of HIVAN in the Asian HIV-infected
population [3], it is not unexpected to find that the
prevalence of HIV infection in the dialysis popula-
tion in Hong Kong is extremely low. Our patient is one
of the few cases ever prescribed peritoneal dialysis
in Hong Kong.
The prevalence of HIV positivity in the dialysis
population is much higher in the USA. According to
the US Renal Data System (USRDS), the prevalence
of HIV-positive dialysis patients is nearly 1% and is
increasing by about 15% to 30% per year. This can
probably be attributed to the large black population
who are at an increased risk of developing HIVAN
[4]. Although HAART slows the progression of HIVAN
to ESRF in many patients [1], in light of the increas-
ing prevalence of HIV infection in the USA, the total
number of patients reaching ESRF is increasing [1].
Both CAPD and hemodialysis are effective modes
of therapy for HIV-positive patients with ESRF. The
prognosis for HIV-positive dialysis patients was dismal
in the pre-HAART era. A substantial improvement in
the prognosis has been observed since the introduction
of HAART. In a retrospective study, patients on
HAART had a significantly lower viral load compared
to those on suboptimal antiretroviral therapy [5]. Four
of seven hemodialysis patients on suboptimal anti-
retroviral therapy died after a mean follow-up period of
13 ( 10 months, while only three of 15 patients on
HAART died after a mean follow-up period of 18 ( 17
months.
Despite encouraging reports, the morbidity and
mortality of these patients remain high compared to
age-matched patients with ESRF due to other causes
[6]. In one study, the mean survival of HIV-positive
ESRF patients was around 15 months compared to 44
months in non-HIV infected patients [7]. In another
series, the 1-year survival of HIV-positive dialysis
patients was only 53% compared to 83% for their
counterparts without HIV infection [8]. Vascular ac-
cess complications including thrombosis and infec-
tion also occur more commonly in HIV-positive hemo-
dialysis patients [1]. In general, a worse outcome is
associated with increasing age at initiation of dialysis
and low CD4 lymphocyte counts.
The main causes of death are infection and mal-
nutrition. This may reflect the underutilization of
HAART in this group of patients. In a retrospective
survey, only 61% of HIV-positive dialysis patients
received HAART [8]. Hypoalbuminemia is reported
to be a strong predictor of mortality in ESRF patients
[9]. In HIV-positive dialysis patients, the problem of
malnutrition is particularly prominent. This may be re-
lated to the, in general, lower socioeconomic status of
HIV-positive ESRF patients. A significantly higher de-
gree of malnutrition at the time of entry and after the
commencement of dialysis has been reported in a na-
tionwide epidemiologic study performed in Italy [10].
Routine HIV testing in dialysis facilities remains
controversial since it may be considered an infraction
of civil liberties. The Centers for Disease Control and
Prevention do not recommend routine screening of
dialysis patients for HIV infection [1]. On the other
hand, the potential advantages of identifying HIV-
positive dialysis patients include better choice of
dialysis modalities, preventive measures to avoid
patient-to-patient transmission, early implementation
of education and counseling programs to prevent
transmission of the virus, use of antiretroviral therapy
at an earlier stage of disease, and better treatment of
opportunistic infections. It is worth noting that HIV
testing employing enzyme immunosorbent assays in
dialysis patients is associated with a high false-positive
rate. Confirmation with the Western blot technique is
mandatory to make a definitive diagnosis [11].
It is prudent to emphasize that universal precautions
must be practiced in all dialysis facilities regardless of
the availability of HIV test results. In light of the rarity
of nosocomial transmission in the dialysis setting [12],
it is generally accepted that universally recommended
precautions and simple maneuvers, such as thorough
cleaning and disinfecting hemodialysis machines after
use, are sufficient to prevent HIV transmission.
CAPD is an alternative therapy for HIV-positive
patients reaching ESRF. Using the USRDS data-
base, the survival of 5,229 HIV-positive hemodialysis
patients was not different from that in 716 peritoneal
dialysis patients [13]. Unlike hemodialysis, no vascular
access is required and, thus, the potential risks of blood
spills, patient-to-patient contamination, activation of
white blood cells, and release of cytokines such as tu-
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mor necrosis factor and interleukin-1 [14], and occupa-
tional exposure of hemodialysis personnel, were mini-
mized [15].
Infectious complications are a major problem asso-
ciated with CAPD. It has been reported that the HIV-
positive CAPD population may develop peritonitis more
frequently than other peritoneal dialysis patients [16].
An array of unusual organisms causing peritonitis has
been reported, including Pasturella multocida,
Trichosporon beifelii and Mycobacterium avium
complex [17]. Owing to the underlying immunodefi-
ciency in HIV-positive dialysis patients, as in our patient,
polymicrobial peritonitis has been reported to be more
common. However, in a retrospective analysis of 80
episodes of polymicrobial CAPD peritonitis in 432
patients, no difference in the polymicrobial peritonitis
rate was observed between HIV-positive and HIV-
negative patients [18].
Peritoneal dialysis effluent (PDE) from HIV-positive
CAPD patients is potentially infectious. Viable and
potentially infectious HIV virus has been isolated from
PDE for up to 7 days in peritoneal dialysis bags at room
temperature and for up to 48 hours in dry exchange
tubing. Therefore, it would appear to be ethical to
inform caregivers of the potential risk of infection. PDE
should be discarded in a sink. A 30-minute exposure to
10% household bleach is an effective viricidal method
to disinfect PDE for disposal [19–21]. Although no case
of HIV transmission to caregivers of HIV-positive
CAPD patients has been reported, personal protective
equipment, including gloves, aprons and face shields,
should be used while disposing of PDE [21].
Similar to the improvements in survival of HIV-
positive patients with the use of HAART, survival of
HIV-positive dialysis patients has also improved. There
are three major classes of antiretrovirals: nucleoside
analog reverse transcriptase inhibitors (NRTIs, e.g.
zidovudine, didanosine, stavudine, lamivudine), non-
nucleoside analog reverse transcriptase inhibitors
(NNRTIs, e.g. nevirapine, efavirenz), and protease
inhibitors (PIs, e.g. saquinavir, ritonavir, indinavir,
nelfinavir). In HAART, a combination of either two
NRTIs with a PI or two NRTIs plus one NNRTI is
employed.
Most HIV medications are well tolerated even in
the presence of renal dysfunction. NRTIs are primarily
excreted by the kidneys. Dosage adjustment is advisable
in patients with renal dysfunction to optimize drug
exposure, reduce the risk of adverse drug effects and
ensure cost-effectiveness in prescribing HAART [22].
A dose reduction of 50% to 70% for NRTIs may be
required, and medications should be administered af-
ter dialysis. In a pharmacokinetic evaluation of lami-
vudine therapy in 11 HIV-positive dialysis patients (9
hemodialysis, 2 CAPD), lamivudine therapy at a
dose of 25 mg/day was equivalent to a drug exposure
of 150 mg twice daily in those with normal renal func-
tion [23]. However, given the safety profile of high-
dose lamivudine therapy, it is not unreasonable to
prescribe lamivudine therapy at a dose higher than
25 mg/day in dialysis patients to prevent under-dosing.
NNRTIs and PIs are primarily metabolized by the liver
cytochrome P450 isoenzyme system, so dose adjust-
ment is not usually required [21]. All patients on
HAART should have their CD4 count and viral load
monitored. Therapeutic drug monitoring is also avail-
able in some centers.
In conclusion, the decisions on whether to initiate
dialytic therapy in HIV-positive ESRF should be
individualized. CAPD is an effective dialytic therapy
for HIV-positive patients, although infection remains
the Achilles’ heel. The potential risk of HIV trans-
mission by PDE should be noted. An understanding
of the pharmacokinetic properties of antiretroviral
drugs in patients with renal dysfunction is mandatory
to ensure safety and cost-effectiveness in prescribing
HAART.
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